LLY · 8-K · 20260805PR000077

Manufacturing Investment and Capex

ELI LILLY & Co · 2026-08-05 · Importance 52 · Surprise 42 · In source text

Lilly committed an additional $4.5 billion to expand manufacturing sites in Indiana.,The investment includes the opening of the company’s first dedicated genetic-medicine facility.,The Indiana commitment was announced alongside new manufacturing capacity intended to support Lilly’s next-generation weight-loss medicine and other products.,The release does not provide a separate quarterly capital-expenditure amount or spending schedule for the $4.5 billion commitment.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
assetspositivecommitted+3.3%Lilly committed an additional $4.5 billion to expand Indiana manufacturing sites and opens first dedicated genetic medicine facility.